Compare JAZZ & NYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | NYT |
|---|---|---|
| Founded | 2003 | 1851 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 12.4B |
| IPO Year | 2007 | 1994 |
| Metric | JAZZ | NYT |
|---|---|---|
| Price | $241.64 | $74.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $217.57 | $72.14 |
| AVG Volume (30 Days) | 843.6K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.16% |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ 4.43 | 0.54 |
| Revenue | $1,618,693,000.00 | ★ $1,783,639,000.00 |
| Revenue This Year | $6.22 | $10.58 |
| Revenue Next Year | $7.68 | $6.98 |
| P/E Ratio | ★ $54.00 | $136.98 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $105.00 | $51.03 |
| 52 Week High | $242.18 | $87.10 |
| Indicator | JAZZ | NYT |
|---|---|---|
| Relative Strength Index (RSI) | 77.45 | 38.70 |
| Support Level | $128.87 | $69.30 |
| Resistance Level | N/A | $86.57 |
| Average True Range (ATR) | 5.98 | 2.52 |
| MACD | 1.05 | -0.38 |
| Stochastic Oscillator | 95.10 | 8.20 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company derives revenue from subscriptions, advertising, and other sources, where the majority of its revenue is generated through subscriptions, which consist of income from standalone and multiproduct bundle subscriptions to its digital products and subscriptions to and single-copy and bulk sales of print products.